Evidence map›Paper›PMID 23569377›Full record

ArticleInternational journal of nanomedicine2013

A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells.

Guanhua Li, Zuojun Hu, Henghui Yin, Yunjian Zhang, Xueling Huang, Shenming Wang, Wen Li

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiOJournal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Guanhua LiDepartment of Vascular and Thyroid Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Zuojun Hu
Henghui Yin
Yunjian Zhang
Xueling Huang
Shenming Wang
Wen Li
Noguchi Thyroid Clinic and Hospital Foundation · JPSun Yat-sen University · CN

Funding

Computerized alcohol screening for children and adolescents (cASCA) in primary caR01AA021904 · NIAAA · BOSTON CHILDREN'S HOSPITAL · PI HARRIS, SION KIM, KNIGHT, JOHN R · 2013 to 2016
$2.4M
NIAAA NIH HHS R01 AA021904
6 · The paper itself

Abstract

The application of RNA interference techniques is promising in gene therapeutic approaches, especially for cancers. To improve safety and efficiency of small interfering RNA (siRNA) delivery, a triblock dendritic nanocarrier, polyamidoamine-polyethylene glycol-cyclic RGD (PAMAM-PEG-cRGD), was developed and studied as an siRNA vector targeting the human ether-à-go-go-related gene (hERG) in human anaplastic thyroid carcinoma cells. Structure characterization, particle size, zeta potential, and gel retardation assay confirmed that complete triblock components were successfully synthesized with effective binding capacity of siRNA in this triblock nanocarrier. Cytotoxicity data indicated that conjugation of PEG significantly alleviated cytotoxicity when compared with unmodified PAMAM. PAMAM-PEG-cRGD exerted potent siRNA cellular internalization in which transfection efficiency measured by flow cytometry was up to 68% when the charge ratio (N/P ratio) was 3.5. Ligand-receptor affinity together with electrostatic interaction should be involved in the nano-siRNA endocytosis mechanism and we then proved that attachment of cRGD enhanced cellular uptake via RGD-integrin recognition. Gene silencing was evaluated by reverse transcription polymerase chain reaction and PAMAM-PEG-cRGD-siRNA complex downregulated the expression of hERG to 26.3% of the control value. Furthermore, gene knockdown of hERG elicited growth suppression as well as activated apoptosis by means of abolishing vascular endothelial growth factor secretion and triggering caspase-3 cascade in anaplastic thyroid carcinoma cells. Our study demonstrates that this novel triblock polymer, PAMAM-PEG-cRGD, exhibits negligible cytotoxicity, effective transfection, "smart" cancer targeting, and therefore is a promising siRNA nanocarrier.

Indexed as

Analysis of VarianceAntineoplastic AgentsApoptosisBlotting, WesternCell Line, TumorCell MembraneCell SurvivalDendrimersDrug CarriersElectrophoretic Mobility Shift AssayERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsGene SilencingHumansLightNanoparticlesAntineoplastic Agentscyclic arginine-glycine-aspartic acid peptideDendrimersDrug CarriersERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsKCNH2 protein, humanPEG-PAMAMPeptides, CyclicPolyethylene GlycolsRNA, Small Interferinganaplastic thyroid cancerdendrimergene silencinghuman ether-à-go-go-related genesmall interfering RNA

Identifiers

PMID23569377
PMCPMC3615931
OpenAlexW1987285727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.